Abstracts tagged "hyperuricemia"

Abstract Number: 234 • 2015 ACR/ARHP Annual Meeting
Weight Variables and Their Association with Serum Urate Concentrations and Hyperuricemia in Young Adults
Angelo L. Gaffo^1,2, David R. Jacobs Jr.³, Huifen Wang⁴ and Kenneth G. Saag⁵, ¹Rheumatology, Birmingham VA Medical Center, Birmingham, AL, ²Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Minnesota, Minneapolis, MN, ⁴Nutritional Epidemiology Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: How body weight, anthropometric parameters, and their changes are associated with serum urate concentrations and hyperuricemia remains unclear. The CARDIA study has been following…
Abstract Number: 2112 • 2015 ACR/ARHP Annual Meeting
Analysis of Gout Subjects Receiving Lesinurad and Allopurinol Combination Therapy By Baseline Renal Function
Kenneth G. Saag¹, Thomas Bardin², Alexander So^3,4, Puja Khanna⁵, Chris Storgard⁶, Scott Baumgartner⁷, Maple Fung⁷, Nihar Bhakta⁷, Scott Adler⁸, Jeff Kopicko⁷ and Michael A. Becker⁹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Lariboisière Hospital, Paris, France, ³Rheumatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland, ⁴CHU Vaudois, University of Lausanne, Lausanne, Switzerland, ⁵Division of Rheumatology/Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ⁶4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ⁷Ardea Biosciences, Inc., San Diego, CA, ⁸AstraZeneca Pharmaceuticals, Wilmington, DE, ⁹University of Chicago, Chicago, IL
Background/Purpose: Two randomized, double-blind, placebo-controlled Phase III clinical trials showed that lesinurad (200 or 400 mg) when added to allopurinol (200-900 mg) significantly increased the…
Abstract Number: 2113 • 2015 ACR/ARHP Annual Meeting
Lesinurad, a Novel Selective Uric Acid Reabsorption Inhibitor, in Combination with Febuxostat, in Patients with Tophaceous Gout
Nicola Dalbeth¹, Graeme Jones², Robert Terkeltaub³, Dinesh Khanna⁴, Jeff Kopicko⁵, Nihar Bhakta⁵, Maple Fung⁵, Chris Storgard⁶, Scott Baumgartner⁵ and Fernando Perez-Ruiz⁷, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ⁷Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: Lesinurad (LESU; RDEA594) is a selective uric acid reabsorption inhibitor (SURI) being investigated for the treatment of gout in combination with a xanthine oxidase…
Abstract Number: 2242 • 2015 ACR/ARHP Annual Meeting
Compliance with Allopurinol Among Hypertensive Patients with Gout Diagnosis and the Relationship to Onset of End-Stage Renal Disease
Sylvie Perreault¹, Javier Nuevo², Scott Baumgartner³ and Robert Morlock⁴, ¹University of Montreal, Montreal, QC, Canada, ²AstraZeneca, Madrid, Spain, Madrid, Spain, ³Ardea Biosciences, Inc., San Diego, CA, ⁴4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: The risk of end-stage renal disease (ESRD) in both hypertension and gout has been examined in the clinical literature. However, the impact of allopurinol…
Abstract Number: 2352 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety in Patients with Tophaceous Gout Receiving Lesinurad and Febuxostat Combination Therapy: Interim Analysis of an Extension Study
Nicola Dalbeth¹, Graeme Jones², Robert Terkeltaub³, Dinesh Khanna⁴, Jeff Kopicko⁵, Scott Adler⁶, Nihar Bhakta⁵, Maple Fung⁵, Chris Storgard⁵, Scott Baumgartner⁵ and Fernando Perez-Ruiz⁷, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶AstraZeneca Pharmaceuticals, Wilmington, DE, ⁷Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: In the randomized, double-blind, placebo-controlled, Phase III CRYSTAL trial, more patients taking lesinurad 200 mg (LESU200) or 400 mg (LESU400), in combination with febuxostat…
Abstract Number: 2353 • 2015 ACR/ARHP Annual Meeting
Lesinurad and Febuxostat Combination Therapy: Analysis of Treatment Based on Patient Baseline Renal Function
Nicola Dalbeth¹, Graeme Jones², Robert Terkeltaub³, Dinesh Khanna⁴, Jeff Kopicko⁵, Scott Adler⁶, Nihar Bhakta⁵, Maple Fung⁵, Chris Storgard⁵, Scott Baumgartner⁵ and Fernando Perez-Ruiz⁷, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶AstraZeneca Pharmaceuticals, Wilmington, DE, ⁷Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: A randomized, double-blind, placebo-controlled, Phase III clinical trial showed that lesinurad, a selective uric acid reabsorption inhibitor (SURI), in combination with febuxostat 80 mg…
Abstract Number: 2095 • 2014 ACR/ARHP Annual Meeting
Two Novel Serum Urate Levels Associated Genetic Loci Identified By GWAS in European Were Confirmed in Chinese Han Population
Minhui Hua¹, Wenfeng Tan² and Miaojia Zhang³, ¹the first affliated hospital with Nanjing medical university, nanjing, China, ²RHEUMATOLOGY DEPT. 300 GUANGZH, THE FIRST AFFILIATED HOSPITAL OF NANJING MEDI, NANJING, China, ³the first affliated hospital with nanjing medical univercity, nanjing, China
Background/Purpose Previous GWAS have identified four novel loci (SNP rs11264341, rs6770152, rs2941484 and rs7224610) were significant with serum urate levels in European . Here, we…
Abstract Number: 1165 • 2014 ACR/ARHP Annual Meeting
Evaluation of Symptom Control Among Treated Gout Patients in the United States, United Kingdom, and Germany
Robert Morlock¹, Chris Storgard², Vernon F. Schabert³, Augustina Ogbonnaya³, Pierre Chevalier⁴, Dionne Hines³ and Sulabha Ramachandran⁵, ¹4939 Directors Place, Ardea Biosciences, San Diego, CA, ²Ardea Biosciences, Inc., San Diego, CA, ³IMS Health, Alexandria, VA, ⁴IMS Health, Vilvoorde, Belgium, ⁵AstraZeneca, Wilmington, DE
Background/Purpose: Gout affects approximately 1-4% of the population in developed Western countries. The hallmark signs of gout are elevated serum uric acid (SUA) level, episodes…
Abstract Number: 179 • 2013 ACR/ARHP Annual Meeting
The Association Between Single Nucleotide Polymorphism ABCG2 rs2231142 and Hyperuricemia: A Case-Control Study
Bingqing Zhang¹, Weigang Fang², Yun Zhang^3,4, Shufen Liu³, Yuanjie Li³ and Xuejun Zeng², ¹Peking Union Medical College, Beijing, China, ²Medicine, Peking Union Medical College Hospital, Beijing, China, ³Peking Union Medical College Hospital, Beijing, China, ⁴Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China
Background/Purpose: The prevalence of hyperuricemia and gout in China increased markedly in the past decades. Genome-wide association studies in Caucasian population have identified multiple…
Abstract Number: 857 • 2013 ACR/ARHP Annual Meeting
Impact of Urate Lowering Therapy On Renal Disease Progression in Patients With Hyperuricemia
Gerald D. Levy¹, T. Craig Cheetham², Nazia Rashid³ and Fang Niu², ¹Int Med/Rheumatology, Southern California Permanente Medical Group, Downey, CA, ²Pharmacy Analytical Services, Kaiser Permanente, Downey, CA, ³Pharmacy Analytical Services, Kaiser Permanente Southern California, Downey, CA
Background/Purpose: The relationship between elevated serum Uric Acid [sUA] and progression of chronic kidney disease is well established.1-3 There are a several small studies on…
Abstract Number: 93 • 2013 ACR/ARHP Annual Meeting
Higher Consumption Of Sugar-Sweetened Soft Drinks Increases The Risk Of Hyperuricemia In Korean Population: The Korean Multi-Rural Communities Cohort Study
Seong-Kyu Kim¹, Jisuk Bae², Jung-Yoon Choe¹, Byung-Yeol Chun³, Pil Sook Park⁴ and Dong Hoon Shin⁵, ¹Catholic University of Daegu School of Medicine, Daegu, South Korea, ²Department of Preventive Medicine, Catholic University of Daegu School of Medicine, Daegu, South Korea, ³Kyungpook National University School of Medicine, Daegu, South Korea, ⁴Kyungpook National University, Daegu, South Korea, ⁵School of Medicine Keimyung University, Daegu, South Korea
Background/Purpose: The aim of this study is to clarify the association between sugar-sweetened soft drinks and fruit drinks made from oranges and apples and the…
Abstract Number: 159 • 2012 ACR/ARHP Annual Meeting
Clinical Efficacy Outcomes with up to 3 Years of Pegloticase Treatment for Refractory Chronic Gout
Michael A. Becker¹, Herbert S. B. Baraf², Robert A. Yood³, Aileen M. Dillon⁴, Janitzia Vazquez-Mellado⁵, Faith D. Ottery⁶, Dinesh Khanna⁷ and John S. Sundy⁸, ¹Medicine, University of Chicago, Chicago, IL, ²Arthritis & Rheumatism Associates, Wheaton, MD, ³Reliant Medical Group, Worcester, MA, ⁴Rheumatology Section, Kaiser Foundation Hospital, San Francisco, CA, ⁵Rheumatology, Hospital General de Mexico, Mexico city, Mexico, ⁶Medical Affairs, Savient Pharmaceuticals, Inc., East Brunswick, NJ, ⁷Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁸Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
Background/Purpose: Pegloticase, a recombinant modified mammalian uricase conjugated to mPEG, was approved for use in refractory chronic gout in the US in 2010. The Phase…
Abstract Number: 160 • 2012 ACR/ARHP Annual Meeting
Pegloticase Long-Term Safety: Data From the Open-Label Extension Trial
Michael A. Becker¹, Herbert S. B. Baraf², Robert A. Yood³, Aileen M. Dillon⁴, Janitzia Vazquez-Mellado⁵, Faith D. Ottery⁶, Dinesh Khanna⁷ and John S. Sundy⁸, ¹Medicine, University of Chicago, Chicago, IL, ²Arthritis & Rheumatism Associates, Wheaton, MD, ³Reliant Medical Group, Worcester, MA, ⁴Rheumatology Section, Kaiser Foundation Hospital, San Francisco, CA, ⁵Rheumatology, Hospital General de Mexico, Mexico city, Mexico, ⁶Medical Affairs, Savient Pharmaceuticals, Inc., East Brunswick, NJ, ⁷Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁸Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
Background/Purpose: Pegloticase is a recombinant modified mammalian uricase conjugated to mPEG and approved for treatment of refractory chronic gout. Pegloticase safety was evaluated during 2…
Abstract Number: 140 • 2012 ACR/ARHP Annual Meeting
Patients That Continue to Flare Despite Apparent Optimal Urate Lowering Therapy
Dinesh Khanna¹, Puja Khanna², David Hagerty³, Chris Storgard⁴, Robert Mischler⁵ and Robert Morlock⁵, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Division of Rheumatology/Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ³Medical, Ardea Bioscience, San Diego, CA, ⁴4939 Directors Place, Ardea Bioscience, San Diego, CA, ⁵Ardea Bioscience, San Diego, CA
Background/Purpose: Gout is a common inflammatory arthritis and its worldwide prevalence is increasing. The purpose of this study is to describe physician, patient and treatment…
Abstract Number: 1901 • 2012 ACR/ARHP Annual Meeting
Chronic Gout. Improvement According to Outcome Meaures in Rheumatology Domains in Daily Clinical Practice
Janitzia Vazquez-Mellado¹, Betsabé Serrano¹, Jaime Mendoza², Sergio Garcia-Mendez¹, V.Chantal Hernández¹, Virginia Pascual Ramos³, Ruben Burgos-Vargas¹ and Marina Rull-Gabayet², ¹Rheumatology, Hospital General de Mexico, Mexico city, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Dept de Immunología y Reumato, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: OMERACT has proposed domains to evaluate the effect of treatment in patients with acute and chronic gout. Their frequency, time to improve and percentage…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].